InvestWiser

Vistin Pharma ASA

VISTNOslo BørsHealthcareMarket value 854 m NOK
19.25NOK +1.3%
last day · Price as of 18 November 2026

The answer first

Does Vistin Pharma beat the market?

No, Vistin Pharma has not beaten the market over the last year.

Vistin Pharma−0.7%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 79% of Nordic stocks

    • Quality92
    • Value56
    • Trend47

    No. 27 of 195 in healthcare

  • Expectations in the price

    Low expectations

    For the share to return about 9% a year from today's price, it is enough that the cash Vistin Pharma keeps shrinks about 3% a year for 10 years.

Max for seven days

Follow Vistin Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Vistin Pharma

From today, at a price of 19.25 NOK. Write why you follow Vistin Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Vistin Pharma

Your first answer is free, no account needed.

Do you own Vistin Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Vistin Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Vistin Pharma−0.7%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Vistin Pharma has fallen 0.7% over the past year, including dividends.
  • Overall, Vistin Pharma ranks better than 79% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 29.4%. The price is 24.5% below its peak now.

Who owns Vistin Pharma? See the major shareholders and their stakes

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

79

Quality, value and trend together. Better than 79% of Nordic stocks.

No. 27 of 195 in healthcare

Quality92
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 30 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns1.02
  • Return on equityProfit divided by equity+18.9%
  • Cash conversionOperating cash flow divided by profit1.65

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value56
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 40 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity2.6
  • P/SPrice divided by sales2.0
  • P/EPrice divided by earnings13.5
  • P/CFPrice divided by operating cash flow8.2

The ranking is built on P/E, P/B and P/S.

Trend47
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 74 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−0.3%
  • 6 months−9.6%
  • 9 months−2.7%
  • 12 months−0.7%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+4.9%
3 years, per year
+1.1%
5 years, per year
+4.4%
10 years, per year
+0.6%
Largest fall, 3 years
−29.4%
From a peak to the bottom
From the peak now
−24.5%
How far the price is from the peak
Volatility, 1 year
24.1%
How much the price swings over a year
Beta, 1 year
0.18
How much the price moves when the market moves

Return with dividends reinvested.

About Vistin Pharma

Vistin Pharma ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 74 employees.

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.

See the full analysis of Vistin Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market